OncLiveTV
OncLive TV provides short, focused interviews with key oncology thought leaders. This unique platform allows oncology professionals to learn about important developments directly from their peers. Additionally, this channel provides OncLive's Peer Exchange video series, which features peer-to-peer discussions of the clinical and practical challenges cancer care professionals face in today's healthcare environment.
Dr. Pennell on Challenges With NGS in Lung Cancer
Dr. Sartor on the Significance of the REASSURE Trial in mCRPC
Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS
Managing Symptoms of NF1
Therapeutic Options for NF1 With PNs
Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes
Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC
Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC
Dr. Weisel on Interim Analysis With Isatuximab Plus KRd in High-Risk Myeloma
Dr. Leslie on the Benefits With Zanubrutinib in MCL
Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models
Signs and Tests for Diagnosis and Prognosis of HCL
Molecular Genetic Changes for Hairy Cell Leukemia
CORRECT, RECOURSE, and ReDOS Trials in mCRC
Later Lines of Therapy for mCRC
Dr. Ghia on Efficacy and Safety of Acalabrutinib in Relapsed/Refractory CLL
. Katz on Redefining Risk Stratification in Prostate Cancer
Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer
Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer
Practical Applications of PRIMA in Ovarian Cancer Management
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
Exploring CAR T-Cell Therapy During COVID-19: What’s on the Horizon for CAR T-Cell Therapy
Using Molecular Testing in GI Cancers
Evolution of NGS Testing in Lung Cancers
CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma
Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of AEs
Understanding the HER2CLIMB Trial
The Benefits of Tucatinib in HER2+ Breast Cancer
Treatment for Metastatic Breast Cancer
A Close Look at Tucatinib in HER+ Breast Cancer
Conventional Versus PSMA Imaging in Prostate Cancer
PSMA-Targeted Imaging in Prostate Cancer
Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AML
Dr. Hope on the Effectiveness of 68Ga-PSMA-11 PET in Prostate Cancer
Dr. Davids on Updated Data With Ibrutinib/Umbralisib in R/R CLL and MCL
Dr. Shore on the Potential Utility of Relugolix in Advanced Prostate Cancer
Dr. Gupta on Challenges With Perioperative Immunotherapy in Bladder Cancers
Dr. Litton on the EMBRACA Trial in Advanced BRCA1/2+ Breast Cancer
Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma
Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCC
Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC
Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer
Metastatic Gastric Cancer: Identifying Disease Progression
Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100
Counseling Patients With mCRPC
CARD Trial In Metastatic CRPC
Dr. Blank on Adjuvant Versus Neoadjuvant Approaches in Stage III Melanoma
Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer
Dr. Bekaii-Saab on Second-Line Treatment Options in HCC
